GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market Challenges
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
Analyst Issues Sell Rating for GlaxoSmithKline Amid Market Share and Litigation Concerns
Analyst Graham Parry of Bank of America Securities maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), retaining the ...
Sudbury11d
Health unit issues advisory for virus vaccine for older adults
Alert sent out to local physicians advises that vaccines should commence for high-risk adults 60 and older for the ...
Saga11d
What is the RSV vaccine? And could it really save your life?
Although the RSV vaccine is new to the NHS ... it more than once in their lives Vaccines against RSV are a recent development. Rival vaccines from GlaxoSmithKline and Pfizer have been licensed for use ...
The Conversation25d
RSV is linked to asthma in children – but we can’t say one causes the other yet
Jane Tuckerman has previously received funding from GlaxoSmithKline (investigator ... Additionally, the RSV vaccine Abrysvo has this year been registered in Australia for use during pregnancy ...
pharmaphorum18d
After GSK stumble, Pfizer moves forward with RSV vaccine
Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV) vaccine in pregnant ... The news comes just days after GlaxoSmithKline called a halt to enrolment ...
pharmaphorum18d
Pfizer raises pressure on GSK, J&J with late-stage RSV vaccine trial
Pfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson & Johnson as the companies strive to bring the first licensed shot to ...
Hosted on MSN15d
HSA approves new RSV vaccine – a breakthrough in elderly respiratory health
has given the green light to the Arexvy vaccine, developed by GlaxoSmithKline, in a groundbreaking move aimed at combating lower respiratory tract disease (LRTD) triggered by respiratory syncytial ...
Investing8d
GSK advances mRNA flu vaccine into phase III trials
In other recent news, GlaxoSmithKline (NYSE ... GSK's respiratory syncytial virus (RSV) vaccine, Arexvy, received approval from the European Commission for use in adults aged 50-59 at increased ...
Investing8d
GSK advances mRNA flu vaccine into phase III trials
In other recent news, GlaxoSmithKline (NYSE:GSK ... GSK's respiratory syncytial virus (RSV) vaccine, Arexvy, received approval from the European Commission for use in adults aged 50-59 at increased ...
GEN4d
StockWatch: Moderna’s $1.1B R&D Cut, Profitability Delay Jolt Investors
Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.
COVID-19
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...